This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Xalkori® (crizotinib) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

GAINOR et al. 2015

XALKORI followed by ceritinib has demonstrated an OS greater than 4 years.1

Similar resistance profile following XALKORI to that seen in other studies2 

23 patients underwent biopsy after progression on XALKORI:1

  • Difficult-to-treat G1202R mutation was not detected.
  • Ceritinib maintained significant antitumour activity after XALKORI.

In patients with brain metastases treated with XALKORI followed by ceritinib (n=25), the median OS from diagnosis was still over 3.5 years.1

* 13.7% of patients received XALKORI in first line; the remainder in second or later lines of therapy; median number of lines of therapy prior to XALKORI was 1 (range 0–8).
27.4% of patients were treated with other therapies between XALKORI and ceritinib.
Of the 73 patients in this study, 25 had brain metastases before initiation of XALKORI, 47 patients did not have brain metastases before initiation of XALKORI and there was no information on one patient.

Adapted from Gainor JF, et al. Clin Cancer Res. 2015;21(12):2745-52.1
Median duration of follow-up was 53.2 months.1
* 13.7% of patients received XALKORI in first line; the remainder in second or later lines of therapy; median number of lines of therapy prior to XALKORI was 1 (range 0–8).

Limitation of the analysis1

Only patients who received both drugs were included in the analysis; those with rapid progression, poor performance status and/or medical comorbidities that did not permit additional therapies/inclusion in a clinical trial may not have been captured in the analysis.

We anticipate that this study will provide a historical context and benchmark for clinical trials evaluating ceritinib and other next-generation ALK inhibitors in the XALKORI-naive setting.​​​​​​​1


References
  1. Gainor JF, Tan DS, De Pas T, et al. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res. 2015;21(12):2745–52.
  2. Gainor JF, Dardaei L, Yoda S, et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016;6(10):1118–33.
  3. XALKORI Summary of Product Characteristics.
PP-XLK-GBR-1170. March 2021

Indication

  • XALKORI as a monotherapy is indicated for:3

    • The first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
    • The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
    • The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)

Register to receive tailored information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No